Study Evaluating Isovorin in Advanced/Recurrent Gastric Cancer
Post-Approved Phase III Study of 1-LV/5FU Therapy
Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
Listed as NCT00195572, this PHASE3 trial focuses on Gastric Cancer and remains completed. Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, it has been updated 7 times since 2002, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
7 versions recorded-
Jan 2026 — Present [monthly]
Completed PHASE3
-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
▶ Show 2 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
May 2002
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Wyeth is now a wholly owned subsidiary of Pfizer
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Adachi-ku, Tokyo, Japan , Anjo, Japan , Aomori, Japan , Chiba, Japan , Chikushino-shi, Japan , Fukuoka, Japan , Fukuroi-shi, Japan , Funai-gun, Japan , Hiroshima, Japan , Ichihara-shi, Japan and 26 more locations